An abstract titled “Impact of JAK Inhibitors on Liver Biochemistries in Patients with Coexisting Autoimmune Hepatitis” was presented at DDW 2026 by co-author Honor Magon on behalf of authors Magnus Chun MD; Daniel Rodriguez, MSc; Jananee Muralidharan, MD; and Aparna Goel, MD. The authors are affiliated with the Department of Internal Medicine at the Kirk Kerkorian School of Medicine at the University of Nevada; the Division of Gastroenterology and Hepatology, Department of Medicine, at the Stanford University School of Medicine; and Atropos Health.
Short Summary:
Individuals with autoimmune hepatitis (AIH) frequently have additional autoimmune conditions, such as inflammatory bowel disease which may require treatment with other immune-modulating therapies, such as Janus Kinase Inhibitors (JAK-inhibitors). The effect of JAK-inhibitors on liver biochemistries in those with AIH is unknown. We examined changes in liver tests and overall safety of JAK-inhibitor therapy in individuals with AIH treated with JAK inhibitors for other clinical indications.